Clinical Trial Update: Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients [Phase 1, Phase 2]

View source ↗

Summary

A pediatric phase 1/2 trial evaluating inhaled iloprost as an adjunct to inhaled nitric oxide for pulmonary hypertension and related neonatal respiratory condit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Neonatal Hypoxic Respiratory Failure
• Persistent Pulmonary Hypertension of the Newborn
• Pulmonary Hypertension
• Respiratory Distress Syndrome

Drugs mentioned

• Iloprost (iloprost)
• Inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Pulmonary Hypertension, Neonatal Hypoxic Respiratory Failure | Phase 1, Phase 2 | Status: WITHDRAWN